BIO.B

Bio-Rad Laboratories, Inc. Class B · NYSE

Sector Health Technology
Industry Medical Specialties
Website -
Employees(FY) -
ISIN US0905721082

Performance

+1.23%

-1.04%

-0.45%

+18.52%

+2.27%

YTD

+2.8%

Profile

Advanced Technical Analysis

Technical Analysis of BIO.B 2024-12-19

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 16 indicating strong downward momentum, a neutral Oscillators Score of 50 suggesting indecision, and a Technical Score of 33 reinforcing the bearish outlook. This combination signals caution for potential investors, as the prevailing trend appears to be nega...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of BIO.B

Stock Rank

Recent News & Updates

2024-12-26 08:47
At US$331, Is It Time To Put Bio-Rad Laboratories, Inc. (NYSE:BIO) On Your Watch List?(Simply Wall St.)
2024-12-23 19:00
BIO: Rating increased to a HOLD(Argus Research)
2024-12-17 19:00
BIO: Lowering target price to $277.00(Argus Research)
2024-12-10 19:00
BIO: Lowering target price to $278.00(Argus Research)
2024-12-09 07:15
RBC Raises Price Target on Bio-Rad Laboratories to $481 From $469, Keeps Outperform Rating(MT Newswires)
2024-12-03 19:00
BIO: Raising target price to $291.00(Argus Research)
2024-11-29 11:31
Bio-Rad (BIO) Down 5.5% Since Last Earnings Report: Can It Rebound?(Zacks)
2024-11-29 07:43
Estimating The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)(Simply Wall St.)
2024-11-26 19:00
BIO: Raising target price to $277.00(Argus Research)
2024-11-24 20:05
Bio-Rad Laboratories, Inc. (BIO): A Bull Case Theory(Insider Monkey)
2024-11-21 09:00
Bio-Rad’s Management to Host Investor Meetings at Citi's 2024 Global Healthcare Conference(Business Wire)
2024-11-13 08:46
What Makes Bio-Rad Laboratories (BIO) an Attractive Opportunity?(Insider Monkey)
2024-11-12 19:00
BIO: Lowering target price to $292.00(Argus Research)
2024-11-05 19:00
BIO: Raising target price to $299.00(Argus Research)
2024-11-04 09:15
Interpreting Bio-Rad (BIO) International Revenue Trends(Zacks)
2024-11-02 08:23
Bio-Rad Laboratories, Inc. (NYSE:BIO) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates(Simply Wall St.)
2024-11-01 06:43
Bio-Rad Laboratories Third Quarter 2024 Earnings: EPS: US$23.37 (vs US$3.65 in 3Q 2023)(Simply Wall St.)
2024-10-31 12:36
Q3 2024 Bio Rad Laboratories Inc Earnings Call(Thomson Reuters StreetEvents)
2024-10-31 11:52
Analyst Report: Bio-Rad Laboratories, Inc.(Morningstar Research)
2024-10-31 11:27
UBS Adjusts Price Target on Bio-Rad Laboratories to $390 From $400, Maintains Buy Rating(MT Newswires)
2024-10-31 09:00
Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference(Business Wire)
2024-10-31 08:42
BIO Q3 Earnings and Revenues Surpass Estimates, Stock Up Aftermarket(Zacks)
2024-10-31 03:18
Bio-Rad Laboratories Inc (BIO) Q3 2024 Earnings Call Highlights: Strong Clinical Diagnostics ...(GuruFocus.com)
2024-10-30 17:50
Bio-Rad Laboratories (BIO) Beats Q3 Earnings and Revenue Estimates(Zacks)
2024-10-30 16:48
Bio-Rad: Q3 Earnings Snapshot(Associated Press Finance)
2024-10-30 16:15
Bio-Rad Reports Third-Quarter 2024 Financial Results(Business Wire)
2024-10-29 11:26
What to Expect From These 3 MedTech Stocks This Earnings Season(Zacks)
2024-10-25 06:34
Shareholders in Bio-Rad Laboratories (NYSE:BIO) have lost 58%, as stock drops 4.6% this past week(Simply Wall St.)
2024-10-23 10:02
Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for(Zacks)
2024-10-23 05:00
FitLife Brands (FTLF) Soars 5.7%: Is Further Upside Left in the Stock?(Zacks)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.